PMID- 34449498
OWN - NLM
STAT- MEDLINE
DCOM- 20210908
LR  - 20231004
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 34
DP  - 2021 Aug 27
TI  - Prognostic values and clinical relationship of TYK2 in laryngeal squamous cell 
      cancer.
PG  - e27062
LID - 10.1097/MD.0000000000027062 [doi]
LID - e27062
AB  - Laryngeal squamous cell cancer (LSCC) is the second most common head and neck 
      cancer with the increasing mortality. The tyrosine kinase 2 (TYK2) has previously 
      been reported to play an important role in various cancers excepting LSCC. We 
      used available data from the cancer genome atlas program (TCGA), gene expression 
      omnibus, and gene expression profiling interactive analysis (GEPIA) to evaluate 
      the role of TYK2 in LSCC.The difference of TYK2 expression level between normal 
      and tumor samples was analyzed based on TCGA, gene expression omnibus, and GEPIA 
      databases. The relationship between clinical features and TYK2 were analyzed 
      using the Wilcoxon signed-rank test. We applied Cox regression and the 
      Kaplan-Meier method to finding which clinical characteristics is associated with 
      overall survival. Also, we used GEPIA database to validate the relationship 
      between TYK2 and overall survival. At last, we performed gene set enrichment 
      analysis based on TCGA data set.The expression level of TYK2 in LSCC was 
      significantly associated with gender, lymph node status and metastasis (P-values 
      <.05). Kaplan-Meier survival analysis, as same as GEPIA validation, demonstrated 
      that LSCC with TYK2-low had a worse prognosis than that with TYK2-high. The 
      univariate analysis showed that TYK2-high correlated significantly with a better 
      overall survival (hazard ratio: 0.351, 95% confidence interval: 0.194-0.637, P < 
      .001). The multivariate analysis revealed that TYK2 remained independently 
      associated with overall survival (hazard ratio: 0.36, 95% confidence interval: 
      0.185-0.699, P = .003). Gene set enrichment analysis shows that Janus 
      kinases-STAT signaling pathway, p53 signalling pathway and natural killer cell 
      mediated cytotoxicity, etc are enriched in TYK2 high expression phenotype.Gene 
      TYK2 may be a potential prognostic molecular marker for LSCC. Moreover, the Janus 
      kinases-STAT signaling pathway and p53 signaling pathway are probably the key 
      pathway associated with TYK2 in LC.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Fang, Lucheng
AU  - Fang L
AD  - First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang 
      Province, China.
FAU - Wang, Wen
AU  - Wang W
AD  - First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang 
      Province, China.
FAU - Shi, Licai
AU  - Shi L
AD  - First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang 
      Province, China.
FAU - Chen, Qinjuan
AU  - Chen Q
AD  - Second Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang 
      Province, China.
FAU - Rao, Xingwang
AU  - Rao X
AUID- ORCID: 0000-0003-3859-0563
AD  - First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang 
      Province, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.2 (TYK2 Kinase)
RN  - EC 2.7.10.2 (TYK2 protein, human)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Biomarkers, Tumor
MH  - Carcinoma, Squamous Cell/mortality/*pathology
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/mortality/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Sex Factors
MH  - TYK2 Kinase/*biosynthesis
MH  - Transcriptome
PMC - PMC10545095
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2021/08/28 06:00
MHDA- 2021/09/09 06:00
PMCR- 2021/08/27
CRDT- 2021/08/27 17:22
PHST- 2021/04/07 00:00 [received]
PHST- 2021/08/03 00:00 [accepted]
PHST- 2021/08/27 17:22 [entrez]
PHST- 2021/08/28 06:00 [pubmed]
PHST- 2021/09/09 06:00 [medline]
PHST- 2021/08/27 00:00 [pmc-release]
AID - 00005792-202108270-00046 [pii]
AID - MD-D-21-02697 [pii]
AID - 10.1097/MD.0000000000027062 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Aug 27;100(34):e27062. doi: 
      10.1097/MD.0000000000027062.